Activation of Nrf2 as a response to cell injury has already been described in different liver cells and several liver diseases, such as cholestatic liver injury [16], viral hepatitis, drug-induced hepatitis, liver fibrosis, and cirrhosis, HCC, and alcoholic and non-alcoholic steatohepatitis [44]. Here, NFE2L2 is linked to hepatocellular carcinoma.